Page 301 - Read Online

Fung et al. Antivirals in hepatitis B hepatocellular carcinoma

Cancer Med 2014;3:390-6. Hepatol 2017; doi: 10.1111/jgh.13848
93. He L, Liu X, Zhao Y, Zhang S, Jiang Y, Wang X, Yang Z. Efficacy 102. Shim JJ, Oh CH, Kim JW, Lee CK, Kim BH. Liver cirrhosis stages
of nucleot(s)ide analogs therapy in patients with unresectable HBV- and the incidence of hepatocellular carcinoma in chronic hepatitis
related hepatocellular carcinoma: a systematic review and meta- B patients receiving antiviral therapy. Scand J Gastroenterol
analysis. Dis Markers 2017;2017:7075935. 2017;52:1029-36.
94. Nagai H, Mukozu T, Matsui D, Kanekawa T, Kanayama M, Wakui 103. Li ZQ, Hu CL, Yu P, Gu XY, Zhang JJ, Li H, Zhang HY, Lv J,
N, Momiyama K, Shinohara M, Iida K, Ishii K, Igarashi Y, Sumino Liu YM, Zeng QL, Yan JY, Yu ZJ, Zhang Y. The development of
Y. Sorafenib prevents escape from host immunity in liver cirrhosis hepatocarcinoma after long-term antivirus treatment of Chinese
patients with advanced hepatocellular carcinoma. Clin Dev Immunol patients with chronic hepatitis B virus infection: Incidence, long-
2012;2012:607851. term outcomes and predictive factors. Clin Res Hepatol Gastroenterol
95. Yang Y, Wen F, Li J, Zhang P, Yan W, Hao P, Xia F, Bi F, Li Q. A high 2017;41:311-8.
baseline HBV load and antiviral therapy affect the survival of patients 104. Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J,
with advanced HBV-related HCC treated with sorafenib. Liver Int Lin L, Xie Q, Bao S, Wang H. Randomized clinical trial: nucleos(t)
2015;35:2147-54. ide analogues improved survival of CHB-related HCC patients
96. Lim S, Han J, Kim GM, Han KH, Choi HJ. Hepatitis B viral load via reducing severity and progression of malignancy. Oncotarget
predicts survival in hepatocellular carcinoma patients treated with 2016;7:58553-62.
sorafenib. J Gastroenterol Hepatol 2015;30:1024-31. 105. Kim JH, Sinn DH, Kim K, Kim H, Gwak GY, Paik YH, Choi MS,
97. Xu L, Gao H, Huang J, Wang H, Zhou Z, Zhang Y, Li S, Chen M. Lee JH, Koh KC, Paik SW. Lamivudine versus entecavir for newly
Antiviral therapy in the improvement of survival of patients with diagnosed hepatitis B virus-related hepatocellular carcinoma. Gut
hepatitis B virus-related hepatocellular carcinoma treated with Liver 2016;10:939-47.
sorafenib. J Gastroenterol Hepatol 2015;30:1032-9. 106. Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed
98. Zhang P, Yang Y, Wen F, Wheeler J, Fu P, Li Q. Cost-effectiveness after curative therapy in patients with HBV-related hepatocellular
analysis of antiviral therapy in patients with advanced hepatitis B carcinoma: an updated meta-analysis. Can J Gastroenterol Hepatol
virus-related hepatocellular carcinoma treated with sorafenib. J 2016;2016:5234969.
Gastroenterol Hepatol 2016;31:1978-85. 107. Xia BW, Zhang YC, Wang J, Ding FH, He XD. Efficacy of antiviral
99. Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of therapy with nucleotide/nucleoside analogs after curative treatment
viral status on survival in patients receiving sorafenib for advanced for patients with hepatitis B virus-related hepatocellular carcinoma: a
hepatocellular cancer: a meta-analysis of randomized phase III trials. systematic review and meta-analysis. Clin Res Hepatol Gastroenterol
J Clin Oncol 2017;35:622-8. 2015;39:458-68.
100. Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van 108. Sun P, Dong X, Cheng X, Hu Q, Zheng Q. Nucleot(s)ide analogues
Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S, Loglio for hepatitis B virus-related hepatocellular carcinoma after curative
A, Siakavelas S, Keskin O, Gatselis N, Hansen BE, Lehretz M, de treatment: a systematic review and meta-analysis. PLoS One
la Revilla J, Savvidou S, Kourikou A, Vlachogiannakos I, Galanis 2014;9:e102761.
K, Yurdaydin C, Berg T, Colombo M, Esteban R, Janssen HLA, 109. Yeh YC, Liu CJ, Kuo RN, Lai CL, Shau WY, Chen PJ, Lai MS.
Lampertico P. The risk of hepatocellular carcinoma is decreasing after Association of adjuvant antiviral therapy with risk of cancer
the first 5 years of entecavir or tenofovir in Caucasians with chronic progression and deaths in patients with hepatitis-B-virus-related
hepatitis B. Hepatology 2017;66:1444-53. hepatocellular carcinoma following curative treatment: a nationwide
101. Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, Park S, Hwang cohort study. PLoS One 2014;9:e102051.
JS. Temporal improvement in survival of patients with hepatocellular 110. Fung J, Lai CL, Seto WK, Yuen MF. Emerging drugs for the treatment
carcinoma in a hepatitis B virus-endemic population. J Gastroenterol of hepatitis B. Expert Opin Emerg Drugs 2016;21:183-93.

Hepatoma Research ¦ Volume 3 ¦ November 27, 2017 293